ED
CLDX icon

Exane Derivatives’s Celldex Therapeutics CLDX Stock Holding History

Exane Derivatives’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,005
Closed -$275K – 526
2014
Q4 		$275K Buy
+1,005
New +$250K 0.04% 187

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exane Derivatives's CLDX Position: Q1 2015 in Review

Exane Derivatives sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 1,005 shares — an estimated $275K sold.

Exane Derivatives first reported a position in CLDX in Q4 2014 and held it in 1 quarter. The position peaked at $275K in Q4 2014. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

  • Exane Derivatives reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Exane Derivatives sold 1,005 Celldex Therapeutics shares in Q1 2015, an estimated $275K.
  • Exane Derivatives first reported a position in Celldex Therapeutics in Q4 2014 and held it in 1 quarter.
  • Exane Derivatives's Celldex Therapeutics position peaked at $275K in Q4 2014.
  • 193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on Exane Derivatives's 13F filing for Q1 2015, filed 15 May 2015.